Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

This study is testing adebrelimab (an immunotherapy drug) combined with a chemotherapy regimen called NALIRIFOX as a first treatment for people with locally advanced (unresectable) pancreatic cancer — cancer of the pancreas that cannot be surgically removed. Researchers want to know if this combination helps shrink tumors and extends survival. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - Your cancer is locally advanced and cannot be removed with surgery - You have not received any prior treatment for pancreatic cancer - Your cancer has at least one measurable area and your organ functions meet required levels **You may NOT be eligible if...** - Your cancer has spread to distant organs (distant metastases) - You have an autoimmune disease or are on immunosuppressive therapy - You have had another cancer requiring treatment - You have HIV, active Hepatitis B or C - You are allergic to the study drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.